Jessica Baker Flechtner

Jessica Baker Flechtner

Company: Genocea Biosciences

Job title: CSO


Unleashing the Titans: The Gen-011 Neoantigen-Targeted Peripheral T Cell Therapy for Solid Tumors 6:00 pm

• Adoptive T cell therapies have resulted in unprecedented efficacy against solid tumors • Prioritizing neoantigens with the ATLASTM bioassay identifies the right targets and avoids pro-tumor InhibigensTM • The GEN-011 neoantigen-targeted peripheral T cells (NPTs) have broad specificity and are non-exhausted, polyfunctional, cytolytic cells • The TITAN-1 clinical trial is ongoing (NCT04596033)Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.